Yoong Sze Lin, Clinton-McHarg Tara, Wolfenden Luke
Hunter New England Population Health, Hunter New England Local Health District, Booth Building, Longworth Avenue, Wallsend, New South Wales 2287, Australia; School of Medicine and Public Health, The University of Newcastle, University Drive, Callaghan, New South Wales 2308, Australia; Priority Research Centre for Health Behaviour, The University of Newcastle, Callaghan, New South Wales 2308, Australia.
Hunter New England Population Health, Hunter New England Local Health District, Booth Building, Longworth Avenue, Wallsend, New South Wales 2287, Australia; School of Medicine and Public Health, The University of Newcastle, University Drive, Callaghan, New South Wales 2308, Australia; Priority Research Centre for Health Behaviour, The University of Newcastle, Callaghan, New South Wales 2308, Australia.
J Clin Epidemiol. 2015 Jul;68(7):788-91. doi: 10.1016/j.jclinepi.2014.12.008. Epub 2014 Dec 30.
To examine the research translation phase focus (T1-T4) of systematic reviews published in the Cochrane Database of Systematic Reviews (CDSR) and Database of Abstracts of Reviews of Effects (DARE). Briefly, T1 includes reviews of basic science experiments; T2 includes reviews of human trials leading to guideline development; T3 includes reviews examining how to move guidelines into policy and practice; and T4 includes reviews describing the impact of changing health practices on population outcomes.
A cross-sectional audit of randomly selected reviews from CDSR (n = 500) and DARE (n = 500) was undertaken. The research translation phase of reviews, overall and by communicable disease, noncommunicable disease, and injury subgroups, were coded by two researchers.
A total of 898 reviews examined a communicable, noncommunicable, or injury-related condition. Of those, 98% of reviews within CDSR focused on T2, and the remaining 2% focused on T3. In DARE, 88% focused on T2, 8.7% focused on T1, 2.5% focused on T3, and 1.3% focused on T4. Almost all reviews examining communicable (CDSR 100%, DARE 93%), noncommunicable (CDSR 98%, DARE 87%), and injury (CDSR 95%, DARE 88%) were also T2 focused.
Few reviews exist to guide practitioners and policy makers with implementing evidence-based treatments or programs.
研究发表在Cochrane系统评价数据库（CDSR）和循证医学数据库（DARE）中的系统评价的研究转化阶段重点（T1 - T4）。简而言之，T1包括基础科学实验的评价；T2包括为制定指南而进行的人体试验的评价；T3包括研究如何将指南转化为政策和实践的评价；T4包括描述健康实践改变对人群结局影响的评价。
对从CDSR（n = 500）和DARE（n = 500）中随机选取的评价进行横断面审核。由两名研究人员对评价的研究转化阶段进行编码，整体以及按传染病、非传染病和伤害亚组分别编码。
共有898项评价研究了传染病、非传染病或与伤害相关的疾病。其中，CDSR内98%的评价聚焦于T2，其余2%聚焦于T3。在DARE中，88%聚焦于T2，8.7%聚焦于T1，2.5%聚焦于T3，1.3%聚焦于T4。几乎所有研究传染病（CDSR为100%，DARE为93%）、非传染病（CDSR为98%，DARE为87%）和伤害（CDSR为95%，DARE为88%）的评价也都聚焦于T2。
几乎没有评价可指导从业者和政策制定者实施循证治疗或项目。
